

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
20-24534
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Use of interferon Gamma to treat AML relapse aft ...	Yes	Self

Description: Use of interferon Gamma to treat AML relapse after allogeneic stem cell transplantation
Patent Status: Pending
Filing Jurisdiction: USA
Licensees:

Licensee	Title	Date
Bolder BioTechnology		

Patent Number: 20200237817
Patent Holder: Current Institution
Additional Information:

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Alvin J Siteman Cancer Research Fund	Grant / Contract	Self
<i>Recipient Name:</i> Eric Duncavage <i>Grant / Contract Description:</i> Grant for 'Development of Next-Generation Karyotyping for Clinical Oncology' <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
BioReference Labs	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consulting for molecular cancer test testing
Bristol-Myers Squibb	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Evening advisory board for molecular diagnostic testing
Cofactor Genomics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Medical director/consultant
Eli Lilly and Company	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Day advisory board for molecular diagnostic testing
Illumina, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Washington University in St. Louis/McDonnell Genome Institute <i>Grant / Contract Description:</i> Sequencing reagents for development of sequencing-based diagnostics <i>Additional Information:</i> Reagents supplied to laboratory		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Cancer Institute	Grant / Contract	Self
<i>Recipient Name:</i> Eric D <i>Grant / Contract Description:</i> R33 CA217700 <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.
- What is the manuscript title?**

Whole Genome Sequencing as a Replacement for Cytogenetics in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as an Alternative to Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Jazz Pharmaceuticals	Grant / Contract	Other - Payments made to institution
<i>Recipient Name:</i> Meagan Jacoby/Washington University <i>Grant / Contract Description:</i> Clinical trial support <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Jazz Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Ad board
Takeda Oncology	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> consulting

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Whole Genome Sequencing as a Replacement for Cytogenetics in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Rapid Whole Genome Sequencing as a Replacement for Conventional Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Rigel Pharmaceuticals	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> Collaboration to identify inhibitors of mutant DNMT3A proteins		<i>Description:</i> Scientific collaborator

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Rapid Whole Genome Sequencing as a Replacement for Conventional Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Rapid Whole Genome Sequencing as a Replacement for Conventional Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Financial Interests

I do not have any financial interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Rapid Whole Genome Sequencing as a Replacement for Conventional Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as an Alternative to Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
PierianDx	Consultant	Self
<i>Category:</i> Consultant		<i>Description:</i> Served as consultant and laboratory director for PierianDx Clinical Laboratory, 01/19-01/20.
<i>Additional Information:</i> This consulting relationship has ended.		

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
"Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies"
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Alvin J. Siteman Cancer Research Fund	Grant / Contract	Self
<i>Recipient Name:</i> David H. Spencer <i>Grant / Contract Description:</i> Grant for 'Development of Next-Generation Karyotyping for Clinical Oncology'		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
Cancer Research Foundation	Grant / Contract	Self
<i>Recipient Name:</i> David H. Spencer <i>Grant / Contract Description:</i> Grant for 'Modeling cancer epigenetic states using patient-derived induced pluripotent stem cells'		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
Doris Duke Charitable Foundation	Grant / Contract	Self
<i>Recipient Name:</i> David H. Spencer <i>Grant / Contract Description:</i> Grant for 'Identifying epigenetic drivers in acute myeloid leukemia' <i>Additional Information:</i>		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research
Illumina, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Washington University in St. Louis/McDonnell Genome Institute <i>Grant / Contract Description:</i> Sequencing reagents were received in-kind for development of sequencing-based diagnostics		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
National Cancer Institute	Grant / Contract	Self
<i>Recipient Name:</i> David H. Spencer <i>Grant / Contract Description:</i> Grant for "Regulatory mechanisms of HOX gene expression in acute myeloid leukemia"		<i>Recipient Type:</i> Individual <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>
Wugen	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Genome analysis consultant
Wugen	Stock Option	Self
<i>Additional Information:</i>		

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?
Yes.
 - Please list the other authors' names here.
Eric J. Duncavage, M.D., Molly C. Schroeder, Ph.D., Michele O'Laughlin, B.S., Roxanne Wilson, B.S., Sandra MacMillan, B.S., Andrew Bohannon, B.S., Scott Kruchowski, B.S., John Garza, B.S., Feiyu Du, M.S., Andrew E. O. Hughes, M.D., Ph.D., Josh Robinson, B.A., Emma Hughes, B.S., Sharon E. Heath, Jack D. Baty, B.A., Julie Neidich, M.D., Matthew J. Christopher, M.D., Ph.D., Meagan A. Jacoby, M.D., Ph.D., Geoffrey L. Uy, M.D., Robert S. Fulton, M.S., Christopher A. Miller, Ph.D., Jacqueline E. Payton, M.D., Ph.D., Daniel C. Link, M.D., Matthew J. Walter, M.D., Peter Westervelt, M.D., Ph.D., John F. DiPersio, M.D., Ph.D., Timothy J. Ley, M.D., and David H. Spencer, M.D., Ph.D.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Astellas Pharma	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Genentech USA, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>
Jazz Pharmaceuticals Inc.	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i>
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i>

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 20-24534

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Pfizer Hematology Global Commercial Steering Committee

Additional Information:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Rapid Whole Genome Sequencing as a Replacement for Conventional Cytogenetics in Myeloid Malignancies
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 20-24534

Summary of Interests

I do not have any interests to disclose at this time.

Additional Information:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Genome Sequencing as a Replacement for Cytogenetics in Myeloid Malignancies
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.